Sweeteners
aspartame increases cancer risk
Leans against Sweeteners 🔬 Includes disconfirming
Part of: • aspartame
RefutedContestedStrong support
consensus score -0.33
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
7 support 8 contradict 1 tested null 8 mixed · 24 sources, 15 independent groups
What the evidence shows
Aspartame was classified by IARC (2023) as 'possibly carcinogenic to humans' (Group 2B) — a category for limited evidence that flags a hazard, not a quantified risk. Human epidemiology is largely reassuring: the Nurses' Health Studies found no breast-cancer link (HR 1.00), reviews find no consistent association, and JECFA reaffirmed the 40 mg/kg/day acceptable intake.
The evidence (24)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Pavanello et al. 2023 · Regul Toxicol Pharmacol | observational | contradicts | moderate | Tox + epi review incl. aspartame genotoxicity/carcinogenicity data: no evidence of cancer risk. |
| Boon D et al 2025 · study_type: meta-analysis | observational | contradicts | moderate | Systematic review (preregistered, OSF) of 90 epidemiology studies covering 6 non-sugar sweeteners (incl. aspartame) and 17 cancer types through Fall 2024; found no consistent associations between any NSS and any cancer type and no dose-resp |
| Huang C et al 2025 · study_type: mechanism | mechanism | mixed | low | Network toxicology/molecular docking analysis (TCGA differential expression + in-silico target intersection) proposes 8 core genes (e.g. EDNRA) linking aspartame to kidney renal papillary cell carcinoma; no wet-lab or epidemiological valida |
| Li et al. 2024 · Br J Nutr | meta-analysis | mixed | moderate | MA: non-nutritive sweeteners not associated with endometrial cancer. |
| Li NR et al 2025 · study_type: mechanism | mechanism | supports | low | Network toxicology + Mendelian randomization + molecular docking/dynamics study proposes aspartame promotes liver cancer via CASP1 (strongest docking affinity -18.45 kJ/mol); MR used to prioritize causal target genes (CASP1 among them) rath |
| Gong Q et al 2026 · study_type: observational | observational | supports | moderate | Mendelian randomization found genetically predicted aspartame intake associated with increased ovarian cancer risk (OR 2.10, 95% CI 1.06-4.18); in vitro validation showed aspartame promoted malignant phenotypes in OC cell lines via AURKA/CC |
| Doueihy NE et al 2025 · study_type: observational | observational | mixed | low | Narrative mini-review of in vitro, in vivo, and epidemiological studies on aspartame carcinogenicity; concludes results are inconsistent, with some studies suggesting an association with high intake and others finding none. |
| Yan et al. 2022 · Nutrients | meta-analysis | supports | low | MA: aspartame subgroup showed a significant cancer association in some analyses, though overall artificial-sweetener effect was null. |
| d10-1093-toxres-tfag049 2026 · Toxicology Research | mechanism | supports | low | Network toxicology + machine learning + molecular docking study intersecting aspartame targets with thyroid-cancer-associated genes (GEO datasets); identifies CTSC, ECE1, F10, HMGCR, APLNR as predictive features with stable docking to aspar |
| Zhu et al. 2026 · J Nutr | observational | mixed | moderate | Large prospective cohort: aspartame–cancer evidence inconsistent, particularly for obesity-related cancers. |
| Hong QY et al 2025 · study_type: observational | observational | supports | low | Broad narrative review of sweeteners' metabolic and cancer effects over the past three decades; concludes excessive/long-term use of 'certain sweeteners' may be associated with malignant tumor occurrence, alongside cardiovascular and metabo |
| Shaher et al. 2023 · Nutrients | observational | mixed | low | Aspartame safety review: epi signals for NHL/myeloma in males; carcinogenicity debate ongoing, chance not excluded. |
| Crick DCP et al 2026 · study_type: observational | observational | tested-null | low | Two-sample Mendelian randomization (UK Biobank n~500,000, FinnGen n~500,000) found no compelling evidence that genetically predicted aspartame taste perception causally affects later-life cancer risk; a weak protective cervical-cancer signa |
| Romanos-Nanclares et al. 2025 · J Natl Cancer Inst | observational | contradicts | high | Nurses' Health Studies: no aspartame–breast-cancer association (HR 1.00 per 200 mg/d), robust to lag analyses. |
| Debras et al. 2022 · PLoS Med | observational | supports | moderate | NutriNet-Santé: aspartame intake associated with slightly higher overall cancer risk (notably breast and obesity-related cancers). |
| Abu-Zaid A et al 2025 · study_type: meta-analysis | meta-analysis | contradicts | moderate | Umbrella review of 10 meta-analyses (35 datasets) of observational studies through Jan 2025: artificial sweetener intake overall not associated with cancer risk (RR 0.99, 95% CI 0.96-1.01), consistent across prospective/case-control designs |
| Marchitti et al. 2025 · Adv Nutr | meta-analysis | contradicts | high | Animal/mechanistic review: no genotoxic/carcinogenic mode of action for aspartame. |
| Haighton et al. 2019 · Regul Toxicol Pharmacol | observational | contradicts | moderate | Quality-appraised aspartame cancer epidemiology: does not support an increased cancer risk in humans. |
| Chen HP et al 2025 · Nutrients | observational | mixed | low | Narrative review of low-calorie sweeteners' metabolic, glycemic, cardiovascular, carcinogenic and gut-microbiota effects; states carcinogenicity concerns are among 'potential risks' but calls for more long-term high-quality trials without n |
| Watling CZ et al 2026 · study_type: observational | observational | contradicts | moderate | Pooled analysis of 11 prospective cohorts (n=1,518,411; 2,811 incident liver cancers); artificially sweetened beverage intake per 1/day was NOT associated with liver cancer, HCC, or ICC risk, while sugar-sweetened beverages were (HCC HR 1.1 |
| Meng K et al 2025 · study_type: animal | animal | contradicts | low | Mouse glioblastoma model with dietary aspartame: metagenomics/transcriptomics showed aspartame did not significantly affect tumor growth, though it altered gut microbiota composition (decreased Rikenellaceae) and upregulated m6A-regulated o |
| Yang H et al 2025 · study_type: observational | observational | mixed | moderate | Two-sample bidirectional Mendelian randomization across 15 tumor types (GWAS instruments for artificial sweetener intake) found artificial sweeteners were protective for breast, gastric, colorectal, prostate, and kidney cancers, but a risk |
| Zhu et al. 2024 · Med Princ Pract | meta-analysis | mixed | moderate | MA: artificial sweeteners not associated with higher colorectal cancer. |
| Zhu Y et al 2026 · study_type: animal | animal | supports | moderate | Apc(min/+) mouse model (subchronic aspartame exposure, 3 months) showed increased proportion of medium-sized small-intestinal tumors vs control, mediated via gut microbiota (A. muciniphila) and serotonin pathway. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.